Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077035 | 0.86 | KCNK3 (0.51) | KMT2AMEN1SMN1; SMN2NPSR1CTSS | |
| SCHEMBL2075968 | 0.82 | HTR7 (0.57) | ALDH1A1GAAKMT2AMAPTTSHR | |
| SCHEMBL2076212 | 0.82 | KCNK3 (0.47) | KMT2AMEN1SMN1; SMN2NPSR1CTSS | |
| SCHEMBL2073889 | 0.82 | HTR7 (0.56) | CTSSKCNK3HTR7HTR1AHTR2A | |
| SCHEMBL2075779 | 0.82 | HTR7 (0.51) | LMNANPSR1CTSSKCNK3MAPT | |
| SCHEMBL2075978 | 0.81 | KCNK3 (0.53) | CTSSKCNK3KDM1AHTR7HTR1A | |
| SCHEMBL2075014 | 0.79 | KCNK3 (0.45) | SMN1; SMN2NPSR1CTSSKCNK3KDM1A | |
| SCHEMBL2075400 | 0.79 | LMNA (0.46) | ALDH1A1LMNACTSSKCNK3MAPT | |
| SCHEMBL2076503 | 0.76 | CTSS (0.46) | KMT2AMEN1SMN1; SMN2NPSR1CTSS | |
| SCHEMBL2074365 | 0.76 | CTSS (0.53) | ALDH1A1LMNACTSSKCNK3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| EP-1668014-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885GAA 3127/4885KMT2A 3501/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885GAA 3127/4885KMT2A 3501/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885GAA 3127/4885KMT2A 3501/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885GAA 3127/4885KMT2A 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.